Tower Research Capital (TRC)’s Relay Therapeutics RLAY Stock Holding History
Bought
Maintained
Sold
Other funds holding RLAY
Tower Research Capital (TRC)'s RLAY Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Relay Therapeutics (RLAY) stake by 42% in Q3 2026, buying an estimated $157K and bringing the position to 27,527 shares worth $497K. The position accounts for 0.01% of the portfolio, ranked #1659.
Tower Research Capital (TRC) first reported a position in RLAY in Q3 2020 and has held it in 25 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q3 2026.
- Tower Research Capital (TRC) held 27,527 shares of Relay Therapeutics worth $497K as of Q3 2026.
- Tower Research Capital (TRC) bought 8,200 Relay Therapeutics shares in Q3 2026, an estimated $157K.
- Relay Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #1659 holding.
- Tower Research Capital (TRC) first reported a position in Relay Therapeutics in Q3 2020 and has held it in 25 quarters since.
- 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.